Skip to content
2000
Volume 20, Issue 37
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Receptor activator of nuclear factor-ΚB ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL-mediated signalling may help develop more sophisticated cell-based therapies to inhibit calcification of the vessel wall.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612820666140212205455
2014-11-01
2025-04-23
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612820666140212205455
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test